AR042046A1 - Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenos - Google Patents
Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenosInfo
- Publication number
- AR042046A1 AR042046A1 ARP030104210A ARP030104210A AR042046A1 AR 042046 A1 AR042046 A1 AR 042046A1 AR P030104210 A ARP030104210 A AR P030104210A AR P030104210 A ARP030104210 A AR P030104210A AR 042046 A1 AR042046 A1 AR 042046A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- heteroaryl
- heteroaralkyl
- aralkyl
- alkyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101710088194 Dehydrogenase Proteins 0.000 title 1
- 239000003098 androgen Substances 0.000 title 1
- 229940030486 androgens Drugs 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 8
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 abstract 3
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 abstract 2
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 abstract 2
- -1 methylenedioxy Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000006872 improvement Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42726302P | 2002-11-18 | 2002-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042046A1 true AR042046A1 (es) | 2005-06-08 |
Family
ID=32326512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104210A AR042046A1 (es) | 2002-11-18 | 2003-11-14 | Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7074795B2 (enExample) |
| EP (1) | EP1562901B1 (enExample) |
| JP (2) | JP4614770B2 (enExample) |
| CN (1) | CN100374421C (enExample) |
| AR (1) | AR042046A1 (enExample) |
| AT (1) | ATE469886T1 (enExample) |
| AU (1) | AU2003290799A1 (enExample) |
| CA (1) | CA2506290C (enExample) |
| CL (1) | CL2003002356A1 (enExample) |
| DE (1) | DE60332862D1 (enExample) |
| ES (1) | ES2345146T3 (enExample) |
| MX (1) | MXPA05005360A (enExample) |
| MY (1) | MY130792A (enExample) |
| PE (1) | PE20040750A1 (enExample) |
| TW (1) | TW200412964A (enExample) |
| WO (1) | WO2004046111A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1744930A (zh) | 2002-12-17 | 2006-03-08 | 先灵公司 | 治疗雄激素依赖性疾病的3型17β－羟基类固醇脱氢酶抑制剂 |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| EP1909797A4 (en) * | 2005-08-02 | 2013-02-27 | Neurogen Corp | DIPIPERAZINYL KETONE AND RELATED ANALOG |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
| EP2702982B1 (en) * | 2011-04-25 | 2016-12-14 | Jun-Hyoung Park | Composition for topical application for preventing hair loss and stimulating hair growth |
| AR096728A1 (es) | 2013-06-25 | 2016-01-27 | Forendo Pharma Ltd | Derivados de estratrieno-tiazol terapéuticamente activos |
| US9850272B2 (en) | 2013-06-25 | 2017-12-26 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 |
| BR112015031846A8 (pt) | 2013-06-25 | 2018-03-06 | Forendo Pharma Ltd | derivados de estratrientiazol, seus usos, e composição farmacêutica |
| US10626140B2 (en) | 2014-12-23 | 2020-04-21 | Forendo Pharma Ltd | Prodrugs of 17β-HSD1-inhibitors |
| US10413557B2 (en) | 2014-12-23 | 2019-09-17 | Forendo Pharma Ltd. | Prodrugs of 17.BETA.-HSD1-inhibitors |
| US10428026B2 (en) | 2015-09-02 | 2019-10-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| UA126342C2 (uk) | 2017-06-08 | 2022-09-21 | Форендо Фарма Лтд | 15-бета-[3-пропанамідо]-заміщені естра-1,3,5(10)-трієн-17-он-сполуки і їх 17-оксими для використання в інгібуванні 17-бета-гідроксистероїддегідрогеназ |
| MA51139A (fr) * | 2017-12-15 | 2020-10-21 | Inthera Bioscience AG | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer |
| CN113412269A (zh) | 2018-12-05 | 2021-09-17 | 佛恩多制药有限公司 | 作为17-hsd1抑制剂的在位置16(17)具有缩合的吡唑环的雌甾-1,3,5(10)-三烯化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE75947T1 (de) | 1984-08-02 | 1992-05-15 | Labrie Fernand | Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs. |
| AU5281990A (en) | 1989-03-10 | 1990-10-09 | Endorecherche Inc. | Combination therapy for treatment of estrogen sensitive diseases |
| ES2133270T3 (es) | 1989-07-07 | 1999-09-16 | Endorecherche Inc | Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna. |
| JP3350048B2 (ja) | 1989-07-07 | 2002-11-25 | アンドルシェルシュ・インコーポレイテッド | アンドロゲン関連疾患の治療方法 |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| ATE197458T1 (de) | 1993-05-17 | 2000-11-11 | Endorech Inc | Verbesserte antiandrogene |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| CA2266015C (en) * | 1996-09-13 | 2003-12-30 | Schering Corporation | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| EP1094798A2 (en) | 1998-03-11 | 2001-05-02 | Endorecherche Inc. | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| ATE350375T1 (de) * | 2001-09-06 | 2007-01-15 | Schering Corp | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen |
| CN1571782A (zh) * | 2001-10-17 | 2005-01-26 | 先灵公司 | 作为3型17β－羟基类固醇脱氢酶抑制剂用于治疗雄激素依赖疾病的哌啶乙酰胺类化合物和哌嗪乙酰胺类化合物 |
-
2003
- 2003-11-14 PE PE2003001156A patent/PE20040750A1/es not_active Application Discontinuation
- 2003-11-14 CA CA2506290A patent/CA2506290C/en not_active Expired - Fee Related
- 2003-11-14 CN CNB2003801086673A patent/CN100374421C/zh not_active Expired - Fee Related
- 2003-11-14 MX MXPA05005360A patent/MXPA05005360A/es active IP Right Grant
- 2003-11-14 MY MYPI20034363A patent/MY130792A/en unknown
- 2003-11-14 WO PCT/US2003/036203 patent/WO2004046111A1/en not_active Ceased
- 2003-11-14 JP JP2004553612A patent/JP4614770B2/ja not_active Expired - Fee Related
- 2003-11-14 ES ES03783382T patent/ES2345146T3/es not_active Expired - Lifetime
- 2003-11-14 AU AU2003290799A patent/AU2003290799A1/en not_active Abandoned
- 2003-11-14 CL CL200302356A patent/CL2003002356A1/es unknown
- 2003-11-14 AR ARP030104210A patent/AR042046A1/es unknown
- 2003-11-14 DE DE60332862T patent/DE60332862D1/de not_active Expired - Lifetime
- 2003-11-14 US US10/713,828 patent/US7074795B2/en not_active Expired - Fee Related
- 2003-11-14 TW TW092131992A patent/TW200412964A/zh unknown
- 2003-11-14 AT AT03783382T patent/ATE469886T1/de not_active IP Right Cessation
- 2003-11-14 EP EP03783382A patent/EP1562901B1/en not_active Expired - Lifetime
-
2006
- 2006-02-24 US US11/362,217 patent/US7476681B2/en not_active Expired - Fee Related
-
2010
- 2010-03-15 JP JP2010058356A patent/JP2010138204A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05005360A (es) | 2005-08-03 |
| US20040127503A1 (en) | 2004-07-01 |
| CA2506290A1 (en) | 2004-06-03 |
| AU2003290799A1 (en) | 2004-06-15 |
| PE20040750A1 (es) | 2004-11-06 |
| JP2010138204A (ja) | 2010-06-24 |
| JP2006513169A (ja) | 2006-04-20 |
| WO2004046111A1 (en) | 2004-06-03 |
| TW200412964A (en) | 2004-08-01 |
| DE60332862D1 (de) | 2010-07-15 |
| MY130792A (en) | 2007-07-31 |
| JP4614770B2 (ja) | 2011-01-19 |
| ES2345146T3 (es) | 2010-09-16 |
| US7074795B2 (en) | 2006-07-11 |
| CN1738800A (zh) | 2006-02-22 |
| HK1073313A1 (en) | 2005-09-30 |
| ATE469886T1 (de) | 2010-06-15 |
| US7476681B2 (en) | 2009-01-13 |
| EP1562901B1 (en) | 2010-06-02 |
| CL2003002356A1 (es) | 2005-02-11 |
| CN100374421C (zh) | 2008-03-12 |
| EP1562901A1 (en) | 2005-08-17 |
| US20060148816A1 (en) | 2006-07-06 |
| CA2506290C (en) | 2012-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042046A1 (es) | Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenos | |
| CO2021003298A2 (es) | Compuestos de sulfonamidaurea novedosos | |
| EA200500723A1 (ru) | Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита c, и связанных с ним заболеваний | |
| AR041724A1 (es) | Compuestos derivados de fenetanolamina y su utilizacion en composiciones farmaceuticas | |
| CO5631431A2 (es) | Indoles sustituidos novedosos | |
| AR048820A1 (es) | Tiadiazolidinonas como inhibidores de la glucogeno sintasa quinasa-3(gsk-3) | |
| CO5290256A1 (es) | Derivados pirazol triciclicos | |
| AR029150A1 (es) | Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende. | |
| AR022203A1 (es) | UN COMPUESTO, PROCESO PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE, Y UN PRODUCTO COMESTIBLE. | |
| DE69833036D1 (de) | Sulfonylderivate | |
| ES2112929T3 (es) | Derivados de acido hidroxamico y composiciones farmaceuticas de ellos. | |
| CO5601020A2 (es) | Compuestos ox-azabiciclicos | |
| AR012032A1 (es) | Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion | |
| PE20221397A1 (es) | Compuestos farmaceuticos | |
| AR061438A1 (es) | Derivados de entacapone | |
| AR044177A1 (es) | Proceso para la preparacion de trans-isomeros de derivados de la difenilazetidinona | |
| ATE460394T1 (de) | 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten | |
| AR112900A1 (es) | Compuesto derivado de pirazol y uso de este | |
| AR071587A1 (es) | Compuestos heterociclicos como inhibidores de mek | |
| ES2079449T3 (es) | 1-aril-1-hidroxi-1-sustituido-3-(4-sustituido-1-piperazinil)-2-propanonas y su utilizacion en el tratamiento de los trastornos neurogenicos de la vejiga. | |
| ES2106185T3 (es) | 3-carboxiesteroides 17-beta-sustituidos no saturados. | |
| AR051734A1 (es) | Regulacion del crecimiento de plantas mediante derivados de 2-amino-6-oxipurina. composiciones. | |
| AR036812A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes | |
| CO4600635A1 (es) | Procedimientos e intermedios para preparar derivados de cromanol sustituidos | |
| MXPA04003195A (es) | Composiciones estabilizadoras termicas para polimeros de vinilo que contienen halogeno. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |